Cipla Q3 Results FY2023, PAT at Rs.801 crores

Cipla Q3 Results FY2023

Corporate Action
by Shreya Anaokar Last Updated: Jan 27, 2023 - 03:41 pm 2.2k Views

On 25th January 2023, Cipla announced its results for the third quarter of FY2023.

Key Highlights:

- Revenues from operations at Rs. 5810 crores
- EBITDA stood at Rs. 1408 crores
- The company reported PAT at Rs. 801 crores

Business Highlights:

- One-India business segment reported a robust double-digit traction in the core portfolio across therapies and business segments; 11% YoY ex-covid growth 
- US business reported highest ever quarterly revenue of $195 Million and 30% YoY growth; Strong traction in the differentiated portfolio including market share expansion in key respiratory and peptide injectable products 
- South Africa, Sub-Saharan Africa, And Global Access (SAGA) business’ supply challenges being addressed 
- International Markets reported revenue impacted by currency volatility; 6% YoY ex-covid growth in INR terms
- API continued growth in emerging markets offsetting normalization in inventory levels for European customers
- R&D investments stand at Rs. 363 crores or 6.2 % of sales; Higher 39% YoY driven by ongoing clinical trials on a respiratory asset and other developmental efforts continuing including biosimilars

Commenting on the results, Umang Vohra, MD and Global CEO, Cipla Ltd, said: “Our Q3FY23 performance reflects sustained momentum in core One-India and US businesses driving our overall revenue growth of 6% reported and 11% on an excovid basis. Our One India franchise delivered strong performance across therapies and segments with double-digit market-beating growth in prescription on a covid adjusted base. We achieved the highest-ever quarterly revenue for the North American region of $195 Mn driven by the contribution of differentiated products and market share expansion in flagship respiratory and peptide franchises. Our reported operating profitability of 24.2% reflects our focused efforts on navigating external headwinds and continued higher R&D spending stemming from ongoing respiratory trials and initiation of biosimilar programs.”

How do you rate this article?

Fill in your details below:

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Shreya Anaokar is a Content Writer at 5paisa. She has completed her Master’s in Finance and Graduation in Statistics from the University of Mumbai. 


Investment/Trading is subject to market risk, past performance doesn’t guarantee future performance. The risk of trading/investment loss in securities markets can be substantial. Also, the above report is compiled from data available on public platforms.

Open Free Demat Account

Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number